Other than the original quoted article from Bioworld and Recce announcing that it is targeting the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) global initiative, which is offering a $1 billion reward for each new antibiotic approved, as well as increased R&D funding, I found the following articles and websites that mention these sort of rewards, there is also the Billions of potential revenue for any company that gets a new superbug antibiotic approved.
https://www.washingtonpost.com/opin...ory.html?noredirect=on&utm_term=.d5077c74e22e
http://www.ip-watch.org/2018/02/15/...d-2018-seeks-partners-antibacterial-research/
http://www.cidrap.umn.edu/news-perspective/2018/01/1-billion-reward-proposed-new-antibiotics
https://www.nature.com/articles/ja2017124
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746591/
Accelerated Approval for RECCE® 327, page-27
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $118.1M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 46.5¢ | 46.5¢ | $2.131K | 4.582K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1263 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 11173 | 5 |
View Market Depth
| Last trade - 12.38pm 04/12/2024 (20 minute delay) ? |
| RCE (ASX) Chart |
